Skip to Main Content

Top of the morning to you. And a steamy one, it is. In fact, there is more steam rising from the grounds of the Pharmalot campus than from our ritual cup of stimulation. But this is to be expected at this time of year, yes? In any event, there is work to be done, so as always, we have assembled a few items of interest for you. After all, the world keeps spinning no matter what the thermometer says. Hope you have a successful day and conquer the world. And of course, do keep in touch. …

Endo International is moving toward a bankruptcy filing, potentially setting off intense conflicts with state and local governments that have sued the pharmaceuticals company for its alleged role in fueling the opioid crisis, The Wall Street Journal reports. Without a deal with opioid plaintiffs after years of negotiations, Endo is considering filing for bankruptcy as a means to restructure its more than $8 billion of debt and thousands of outstanding lawsuits. Other pharmaceutical companies, including Purdue Pharma and Mallinckrodt, have sought bankruptcy protection to resolve opioid liabilities, filing for chapter 11 with settlements in place with most U.S. states.


Teva Pharmaceuticals is taking a long-running battle over generic drug labeling to the U.S. Supreme Court, Bloomberg News writes. The petition comes after a federal appeals court twice ruled that Teva labeling on a copycat version of a GlaxoSmithKline heart drug led doctors to prescribe the generic for an infringing use. The dispute centers on “skinny labeling,” a practice in which a generic company leaves the patented uses of a name-brand drug off its labels. This tactic has been a linchpin among generic companies ever since a federal law known as the Hatch-Waxman Act went into effect nearly four decades ago.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.